Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors
Linda A. Snyder(Ortho Clinical Diagnostics (United States)), Rao N. V. S. Mamidi(Janssen (United States))
Cited by 4
Related Papers
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target
|Journal of Clinical Investigation|2020|133